Halozyme Therapeutics Inc (HALO)
49.00
+3.30
(+7.22%)
USD |
NASDAQ |
Nov 22, 16:00
48.52
-0.48
(-0.98%)
Pre-Market: 20:00
Halozyme Therapeutics Cash from Financing (Quarterly): 18.56M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 18.56M |
| June 30, 2024 | 9.482M |
| March 31, 2024 | -0.489M |
| December 31, 2023 | -249.92M |
| September 30, 2023 | 4.101M |
| June 30, 2023 | 2.446M |
| March 31, 2023 | -164.61M |
| December 31, 2022 | 6.329M |
| September 30, 2022 | -12.40M |
| June 30, 2022 | 367.82M |
| March 31, 2022 | 0.624M |
| December 31, 2021 | -156.01M |
| September 30, 2021 | -60.07M |
| June 30, 2021 | -44.76M |
| March 31, 2021 | 338.70M |
| December 31, 2020 | -27.40M |
| September 30, 2020 | -43.85M |
| June 30, 2020 | 13.59M |
| March 31, 2020 | -48.62M |
| December 31, 2019 | 210.42M |
| September 30, 2019 | -19.25M |
| June 30, 2019 | -16.22M |
| March 31, 2019 | -21.73M |
| December 31, 2018 | -18.35M |
| September 30, 2018 | -16.42M |
| Date | Value |
|---|---|
| June 30, 2018 | -16.37M |
| March 31, 2018 | -12.65M |
| December 31, 2017 | 0.082M |
| September 30, 2017 | -0.89M |
| June 30, 2017 | 135.84M |
| March 31, 2017 | -3.382M |
| December 31, 2016 | 0.279M |
| September 30, 2016 | 0.476M |
| June 30, 2016 | 5.42M |
| March 31, 2016 | 144.45M |
| December 31, 2015 | 1.731M |
| September 30, 2015 | 0.437M |
| June 30, 2015 | 3.773M |
| March 31, 2015 | 7.157M |
| December 31, 2014 | 2.471M |
| September 30, 2014 | 0.795M |
| June 30, 2014 | 1.201M |
| March 31, 2014 | 110.03M |
| December 31, 2013 | 23.07M |
| September 30, 2013 | 2.303M |
| June 30, 2013 | -0.055M |
| March 31, 2013 | -0.252M |
| December 31, 2012 | 29.74M |
| September 30, 2012 | 0.0389M |
| June 30, 2012 | -0.09M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-249.92M
Minimum
Dec 2023
367.82M
Maximum
Jun 2022
8.197M
Average
0.0675M
Median
Cash from Financing (Quarterly) Benchmarks
| Lexicon Pharmaceuticals Inc | -0.916M |
| Novavax Inc | -0.097M |
| Kura Oncology Inc | 2.202M |
| TransMedics Group Inc | 7.862M |
| Pulmonx Corp | 0.459M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 115.38M |
| Cash from Investing (Quarterly) | -167.48M |
| Free Cash Flow | 392.71M |
| Free Cash Flow Per Share (Quarterly) | 0.8749 |
| Free Cash Flow to Equity (Quarterly) | 112.22M |
| Free Cash Flow to Firm (Quarterly) | 117.61M |
| Free Cash Flow Yield | 6.17% |